ANNUAL REPORT 2012

Financials

CONSOLIDATED FINANCIAL STATEMENTS, IFRS



Consolidated income statement


EUR million Note 2012
2011
Net sales 2 747.8
742.5
Cost of goods sold 6 -475.4
-483.3
Gross profit
272.4 36% 259.2 35%







Other operating income 5 2.1
2.2
Sales and marketing expenses 6 -128.9
-126.3
Administration expenses 6 -73.5
-64.0
Research and development costs 6 -8.1
-8.6
Other operating expenses 6 -0.1
-9.7
Operating profit
63.9 9% 52.8 7%







Change in fair value of biological assets 14 5.6
-1.0
Share of profit from associate 16 47.8
42.7
Gain on sale of associate shares 16 87.0
69.8
Other financial income and expenses 8 -3.8
-2.4
Profit before taxes
200.4 27% 161.8 22%







Income taxes 9 -21.5
-5.5







Profit for the period
178.9 24% 156.3 21%







Attributable to:




Equity holders of the parent company
178.9
156.3







Earnings for equity holders of the parent company




per share, euro (basic and diluted) 10 2.18
1.91







Consolidated statement of comprehensive income


EUR million Note 2012
2011
Profit for the period
178.9
156.3







Translation differences
-1.0
3.9

transferred to income statement


-0.5
Change in associate recognized




directly in other comprehensive income 16 0.3
-2.0

transferred to income statement
-0.1
-0.4
Cash flow hedges
-0.8
-0.5
Defined benefit plan actuarial




gains (losses) net of tax
-0.5
-0.3
Other comprehensive income for the period net of tax
-2.2
0.2







Total comprehensive income for the period
176.7
156.6







Attributable to:




Equity holders of the parent company
176.7
156.6














The notes are an integral part of these consolidated financial statements.